Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10047707HBVENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS30004286HIVENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS30073364HIVENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS20064517HPVENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS20045826HPVENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS44010334HTLV-1ENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS44032237HTLV-1ENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TVIS44018465HTLV-1ENSG00000072133.12protein_codingRPS6KA6NoNo27330Q9UK32
TCGA Plot Options
Drug Information
GeneRPS6KA6
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009380
UniProt IDQ9UK32
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830